Relmada Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Relmada Therapeutics Inc.
- Former names
- Camp Nine, INC.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Coral Gables
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RLMD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001553643
- EIN
- 45-5401931
Board of directors
-
Charles J. Casamento · DirectorSince 2023
-
Eric Thomas Schmidt · DirectorSince 2023
-
Fabiana Fedeli · DirectorSince 2023
-
John Glasspool · DirectorSince 2023
-
Paul Edward Kelly · Director · COOSince 2023
-
Sergio Traversa · Director · Chief Executive OfficerSince 2023
Chief executives
Sergio Traversa
· Chief Executive Officer
Dates unknown
Board connections
2 of this board's directors also sit on 4 other boards.
- via Charles J. Casamento
- via Charles J. Casamento
- via Charles J. Casamento
- via Eric Thomas Schmidt
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $4,030,050
- 10 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +100,000 | $4.10 | $410,000 |
| Sep 10, 2026 | Shenouda Maged Officer (Chief Financial Officer) | Open-market purchase | +79,800 | $4.25 | $339,150 |
| Sep 9, 2026 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +100,000 | $4.18 | $418,000 |
| Sep 9, 2026 | Shenouda Maged Officer (Chief Financial Officer) | Open-market purchase | +120,200 | $4.20 | $504,840 |
| Dec 15, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +27,500 | $4.12 | $113,300 |
| Dec 15, 2025 | Shenouda Maged Officer (Chief Financial Officer) | Open-market purchase | +11,665 | $4.12 | $48,060 |
| Nov 5, 2025 | Ence Chuck Officer (CAO and COO) | Open-market purchase | +136,000 | $2.20 | $299,200 |
| Nov 5, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +272,500 | $2.20 | $599,500 |
| Nov 5, 2025 | Shenouda Maged Officer (Chief Financial Officer) | Open-market purchase | +500,000 | $2.20 | $1,100,000 |
| Nov 5, 2025 | Paul Edward Kelly Director, Officer (Chief Operating Officer) | Open-market purchase | +90,000 | $2.20 | $198,000 |
| Aug 28, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +55,976 | $0.74 | $41,422 |
| Aug 27, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +129,455 | $0.67 | $86,735 |
| Aug 26, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +80,545 | $0.62 | $49,938 |
| May 20, 2025 | Shenouda Maged Officer (Chief Financial Officer) | Open-market purchase | +60,000 | $0.52 | $31,200 |
| May 20, 2025 | Sergio Traversa Director, Officer (Chief Executive Officer) | Open-market purchase | +147,686 | $0.56 | $82,704 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.